Nitin Jain, MD, on a Triplet Regimen for Richter Transformation

December 18, 2025 By The ASCO Post Staff

Nitin Jain, MD, of The University of Texas MD Anderson Cancer Center, reviews findings from a phase II trial of pirtobrutinib, venetoclax, and obinutuzumab for patients with Richter transformation (Abstract 89). 

Related Content